Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Sphere Medical appoints Spanish distributor

Proyectos Hospitalarios Internacional is well established in Spain as a distributor of a variety of medical devices, including a number in the critical care arena
Operating theatre
Proxima 4 is used to monitor patients in the intensive care unit and operating room.

Medical diagnostics device maker Sphere Medical Holdings PLC (LON:SPHR) has appointed Proyectos Hospitalarios Internacional (Prhoinsa) as its exclusive distributor of products in Spain.

Prhoinsa is well established in Spain as a distributor of a variety of medical devices, including a number in the critical care arena, Sphere said.

The news comes hot on the heels of yesterday’s announcement about the European launch of Proxima, the next generation of Sphere’s blood gases monitor.

Prhoinsa will start marketing Proxima in the second quarter of next year.

It has already placed initial orders for Proxima 4 monitors.

Sphere already has a distributor in Italy, while it markets its products directly in the UK, Germany, Belgium and the Netherlands.

The company is working on securing distribution deals for other European countries.

"We are very pleased to appoint Prhoinsa as our distributor of Proxima in Spain and we look forward to expanding our geographical coverage further in the coming months, particularly now that Proxima 4 has been launched,” said Wolfgang Rencken, chief executive officer of Sphere.

Shares in Sphere were 2.3% higher at 10.1p on the news.

John-H.jpg
Why Invest In Sphere Medical Holding PLC? Read More Here

Register here to be notified of future SPHR Company articles
View full SPHR profile View Profile

Sphere Medical Holding PLC Timeline

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use